跳至主要内容
临床试验/NCT05873725
NCT05873725已完成不适用

Retrospective Study of High Dose Follitropin Delta in a Mixed Protocol With Human Chorionic Gonadotropin

Clinique Ovo1 个研究点 分布在 1 个国家目标入组 118 人开始时间: 2023年5月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
118
试验地点
1
主要终点
Number of good quality blastocysts

研究概览

简要总结

Follitropin delta is a rFSH, uniquely expressed in a human fetal retinal cell line, which owing to differences in glycosylation profile has a lower clearance and induces a higher ovarian response in humans than existing rFSH preparations when administered at equal doses of biological activity. A noninferiority clinical trial (ESTHER-1) in which individualized dosage of follitropin delta according to each patient's profile (AMH and weight) was compared to conventional follitropin alfa dosing for IVF have demonstrated that an individualized follitropin delta dosing is noninferior to conventional follitropin alfa with respect to ongoing pregnancy rate, ongoing implantation rate, and also live births, with a concomitant reduction in iatrogenic complications, including OHSS

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 42 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Women 18 to 42 years of age undergoing IVF/ICSI cycle
  • IVF antagonist protocol
  • Regular menstrual cycles of 24-35 days
  • Presence of both ovaries

排除标准

  • Endometriosis stage III/IV
  • History of recurrent miscarriages, defined as ≥ 3 consecutive losses
  • Women undergoing ovarian stimulation for oncologic or elective fertility preservation
  • Women participating in any other research project
  • Hypersensitivity to follitropin delta and/or human chorionic gonadotropin
  • Use of Growth Hormone (GH) during the stimulation cycle

研究组 & 干预措施

Follitropin delta + hCG

Combination of follitropin delta and serial hCG injections at individualized doses, where dosing regimen was determined according to AMH and weight in women undergoing an IVF antagonist cycle

干预措施: Follitropin delta (Drug)

Follitropin delta + HP-hMG

Combination of follitropin delta and highly-purified human menopausal gonadotropin (HP-hMG) where dosing regimen was determined according to AMH and weight in women undergoing an IVF antagonist cycle

干预措施: Follitropin delta (Drug)

结局指标

主要结局

Number of good quality blastocysts

时间窗: Up to 6 day

Number of good quality oocytes fertilized

次要结局

未报告次要终点

研究者

发起方
Clinique Ovo
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验